Osteonecrosis after hematopoietic SCT (HCT) has seldom been addressed in pediatric populations. At our institution, since January 2002, children undergoing allogeneic HCT (alloHCT) receive yearly follow-up magnetic resonance imaging (MR) of hips and knees. To estimate the prevalence, longitudinal changes and associated risk factors for osteonecrosis after alloHCT, we reviewed MRs for children who underwent single alloHCT during the study period. We analyzed 149 of 344 patients who had post-HCT MR imaging performed (84 males; median age 11 years (range, 0.5 --21years)), median follow-up time was 32.6 months (range, 2.8 --97.2 months). In all, 44 (29.5%) developed osteonecrosis of hips and/or knees; of those, 20 (45%) had at least 30% epiphyseal involvement. In 23 (52%), osteonecrosis lesions were identified in the first and in 43 (98%) by the third yearly scan. Knees were more frequently involved than hips; severity of osteonecrosis was greater in hips. Those who had prealloHCT osteonecrosis, two patients' hips and six patients' knees resolved completely; three patients' osteonecrosis lesions regressed after alloHCT. On risk factor analysis, age at time of alloHCT (P ¼ 0.051) and osteonecrosis identified by MRs before alloHCT (P ¼ 0.001) were the primary risk factors. This analysis shows that preventive strategies for osteonecrosis in this population should focus on measures to minimize risk factors before alloHCT.
INTRODUCTION
The increased use of hematopoietic SCT (HCT) among children, coupled with an increase in survival, has led to a rise in the number of young HCT survivors. 1, 2 Osteonecrosis, a debilitating skeletal morbidity 3, 4 is one complication that can compromise quality of life among these survivors. Osteonecrosis is a challenge to treat in this population because it is often identified in advanced stages, and in multiple joints, when the only available treatment is joint replacement. Surgery can be accompanied by high rates of infection because of immunosuppression, and often requires revision because of hardware failure in these young patients. 5, 6 Although published reports describe osteonecrosis in adults or mixed populations, 2,3,7 --11 studies describing osteonecrosis exclusively in the pediatric population are few. 12 --16 A wide range of incidence rates, 3.9 --44.0%, following pediatric HCT is reported. Among adults, the incidence of osteonecrosis is higher in allogeneic than in autologous HCT survivors 3, 7, 11 Previously reported risk factors for osteonecrosis include acute and chronic GVHD requiring steroids, older age at transplantation, and a primary diagnosis of leukemia or aplastic anemia. 2, 3, 9, 11, 12 Limiting understanding of osteonecrosis in pediatric HCT patients are the diverse diagnostic criteria used in previous studies, 3, 8, 11, 12, 17, 18 ranging from symptom-based diagnosis and plain radiographs to magnetic resonance imaging (MR) studies.
We reviewed prospectively acquired serial MRs in children who underwent a single allogeneic HCT (alloHCT) at our institution from December 2000 to September 2007. We sought to assess the prevalence, associated risk factors and longitudinal changes observed over time in the development of osteonecrosis after alloHCT. This knowledge provides an assessment of the magnitude of this problem and an understanding of the timing of onset of osteonecrosis in this vulnerable young population.
METHODS

Study population
We retrospectively reviewed medical records and MRs of children who underwent a single alloHCT at St Jude Children's Research Hospital between December 2000 and September 2007. Only patients for whom post-HCT MRs of hips, knees or both was available were included in the cohort. To assess the representativeness of the study sample, clinical characteristics of the cohort were compared with those of the excluded population.
Since January 2002, patients undergoing alloHCT at St Jude have undergone baseline MR of the hips and knees at the time of alloHCT, and follow-up protocol-driven imaging of hips and knees annually afterward. If BMT must be performed urgently, then pre-alloHCT MR imaging may be omitted. If the second follow-up MR is normal and the patient is asymptomatic, then no further imaging is done. If the study is abnormal or symptoms persist during the second annual imaging study, then the patient is followed until imaging findings peak or symptoms resolve.
Institutional review board approval was obtained for this study, and data were managed in accordance with the Health Insurance Portability and Accountability Act of 1996. All patients underwent institutional review board-approved treatment for their primary disease under institutional or cooperative group protocols.
Osteonecrosis
Patients being evaluated for osteonecrosis had coronal noncontrast T 1 -weighted and short tau inversion recovery imaging of the hips and/or knees, and sagittal fast low angle shot MR 2D imaging of the articular surfaces. MRs were performed with either a Siemens 1.5 --T Symphony or a Vision MR unit (Siemens, Inc., Erlangen, Germany). MRs were reviewed and interpreted by an experienced pediatric radiologist (SCK) blinded to the presence or absence of clinical symptoms. As described previously, 5, 19, 20 osteonecrosis was defined as a geographical area of decreased signal on T1-weighted and increased signal on short tau inversion recovery images.
Osteonecrosis locations were classified as epiphyseal, metaphyseal or diaphyseal. 19 Because the extent of epiphyseal involvement is an important predictor of joint outcome, 5 we categorized the extent of epiphyseal involvement as X30% or o30% of the weight-bearing surface. Thus, hip joint involvement was coded according to the involvement of the capital femoral epiphysis, and knees were coded as involved if an osteonecrosis lesion was present in either the distal femoral or the proximal tibial epiphysis. For patients who underwent multiple MRs after alloHCT (N ¼ 91), the MR revealing the most severe osteonecrosis was used for calculating prevalence and analyzing risk factors. We also evaluated the distribution and pattern of multiple joint involvements.
Longitudinal changes in osteonecrotic lesions
Serial MRs were evaluated to assess the evolution of osteonecrosis over time. Longitudinal changes were documented separately for knees and hips by comparing annual MRs after alloHCT and by comparing pre-and post-alloHCT MRs for patients for whom pre-alloHCT MRs were available.
Any case that resolved completely over time (hip or knee) bilaterally was classified as 'resolved'; any decrease in size of the osteonecrosis lesion was categorized as 'regression'. Patients with negative pre-alloHCT MR who had osteonecrotic lesions after alloHCT and those identified with osteonecrosis after alloHCT for the first time were considered as 'new cases'. Cases with an increase in the size of existing osteonecrosis lesions were labeled as 'progression'. We also collected information about surgical interventions for osteonecrosis during the follow-up period.
Transplantation
All patients underwent alloHCT on institutional review board-approved protocols. Grafts were obtained from HLA-identical siblings, matched unrelated donors (matched for five or six HLA loci) or mismatched family members. Patients with hematological malignancies were conditioned with myeloablative TBI-based conditioning (12 Gy in eight fractions over 4 days at doses of 150 cGy per fraction) or with reduced-intensity fludarabine-based conditioning (40 mg/m 2 for 5 days). Patients with nonmalignant conditions were given BU-based conditioning (8 --16 mg/ kg). All recipients received either a calcineurin inhibitor or mycophenolate mofetil for GVHD prophylaxis.
GVHD was graded according to standard criteria. 21, 22 Patients with grade 2 to 4 acute GVHD were treated with methylprednisolone (1 --2 mg/ kg daily). If GVHD remained at grade X2 for 47 days or progressed, secondary agents were started, such as a calcineurin inhibitor or mycophenolate mofetil that the patient was not receiving.
Risk factors
We considered associations between osteonecrosis after alloHCT and the following risk factors: sex, race, age at time of alloHCT (that is, o10 years or X10 years), age at primary diagnosis, primary diagnosis (lymphoid malignancies and aplastic anemia vs others), body mass index at time of alloHCT (normal and underweight vs overweight and obese), donor type (related vs unrelated), conditioning regimen (TBI vs non-TBI), acute GVHD (none vs grade X1), chronic GVHD (none vs limited and none vs extensive) and physis status at the time of HCT (open vs closed). Body mass index at the time of HCT was calculated only for patients 42 years, per Centers for Disease Control and Prevention criteria (www.cdc.gov/healthyweight/ assessing/bmi/childrens_bmi/about_childrens_bmi.html). 23 As physeal development was bilaterally similar (correlation coefficient40.95 with Po0.0001; results not shown) and there were only minor differences between hips and knees (correlation coefficient around 0.85 with Po0.0001), we used a majority rule to combine all six physis statuses into one status value. For patients with more than half physis statuses as 'closed,' we defined the physis status as 'closed. ' As previously described, 19 malignant conditions were categorized as lymphoid (that is, ALL, non-Hodgkin lymphoma and Hodgkin disease) or non-lymphoid (malignant conditions other than described as lymphoid). Because statistical power for eliciting the effect of individual treatment regimens was limited and individual cumulative doses of steroids received by each patient were unavailable, primary diagnoses were categorized on the basis of contemporary treatment protocols to assess the potential effect of steroid exposure. Diagnoses were grouped as follows: lymphoid malignancies and aplastic anemia vs other conditions (that is, nonlymphoid malignancies and sickle cell disease, immunodeficiency syndromes, osteopetrosis, I-cell disease, Hurler disease, thromboasthenia and Glanzmann disease).
Statistical analyses
Descriptive statistics were used to describe the study population by sex, race, primary diagnosis, age at the time of MR; age, body mass index and physis status at the time of HCT, conditioning regimen, product type, donor type, donor match type, acute and chronic GVHD grades and duration of chronic GVHD.
Osteonecrosis prevalence rates were calculated for epiphyseal involvement of any of the four lower extremity joints, and for hips and knees separately. Time to development of osteonecrosis after alloHCT was calculated only for children with negative or undetected osteonecrosis before alloHCT. The pattern and distribution of joint involvement was examined by evaluating the number of lower extremity joints involved at the time when the earliest MR showed the highest grade of osteonecrosis. Cumulative incidences (CI) of osteonecrosis after alloHCT were estimated with death as the competing event.
We used a generalized estimating equation models 24 to estimate the incidence of osteonecrosis over time. Independent variables with a significance level of 0.01 in univariate analysis were included in the multivariate generalized estimating equation model. Because sickle cell anemia 25 is highly correlated with black race, the analysis was repeated with and without sickle cell patients in the model. Data were analyzed by using SAS (Version 9.13; SAS Institute, Inc., Cary, NC, USA). Statistical significance was set at a P-value of 0.05.
RESULTS
Demographic characteristics of the study population Of the 344 consecutive patients who underwent alloHCT at St Jude Children's Research Hospital from December 2000 to September 2007, 149 (84 males) children (median age at time of alloHCT 11 years (range, 0.5 --21 years)) underwent at least one post-alloHCT MR of hips and/or knees irrespective of symptoms, and had undergone a single alloHCT (Figure 1 ). Demographic characteristics of the cohort are shown in Table 1 . In all, 116 patients had alloHCT for malignant diseases and 33 for nonmalignant conditions. Median time to follow-up from the date of alloHCT was 32.6 months (range, 2.8 --97.2 months). When compared with excluded patients, the study population was older at the time of alloHCT, had fewer males and more often received TBI. Patients 410 years of age were more likely to have undergone pre-alloHCT MR than those o10 years (Po0.0001) at the time of BMT (Table 2) .
Prevalence, severity and time to development of osteonecrosis When considering all four joints, the prevalence of osteonecrosis was 29.5% (44/149); 45.5% (20/44) had X30% epiphyseal involvement. The prevalence of osteonecrosis in the knees was 28.2% (40/142), greater than the prevalence of 9% (13/143) in hips. Of the 40 patients with osteonecrosis of the knees, 14 had X30% epiphyseal involvement. A total of 12 out of the 13 patients with hip osteonecrosis had X30% epiphyseal involvement. CI plots (Figure 2) show that 52.3% (23/44) of osteonecrosis cases were identified in the first, and 97.8% (43/44) by the third annual scans.
Among the 44 children with osteonecrosis after alloHCT, 14 had evidence of osteonecrosis on pre-alloHCT MR. Median times to development of osteonecrosis in any joint in children with unknown pre-alloHCT osteonecrosis status (n ¼ 16), and in children with negative pre-alloHCT status (n ¼ 14) were 12.4 months (0.2 --38.7 months) and 12.2 months (0.2 --24.4 months), respectively.
Pattern of joint involvement
Of the 44 patients with osteonecrosis, 30 (68.2%) had multiarticular involvement, most commonly, bilateral knee involvement (21/44) . In all, 3 of these patients had bilateral hip coupled with uni-or bilateral knee involvement. Of the 14 of 76 children who had both pre-and post-alloHCT MR, 9 were found to have multiarticular involvment. 
Longitudinal changes
Among the 149 patients, 58 had only one post-HCT imaging study available for review, 32 had two and 59 had more than two. Pre-HCT imaging studies were available for 76 children (Figure 1) . 19 During the first year after alloHCT, hip MRs were available for 124 and knee MRs for 129 patients (Table 3) . Of the 129 patients with first annual hip MRs, 58 also had pre-alloHCT MRs; two showed complete resolution, and seven new cases of osteonecrosis were identified. For knees, 57 of 129 had pre-alloHCT MRs; 2 showed complete resolution, 1 regressed and 25 new cases were identified.
During the second year after alloHCT, 124 patients had hip MRs for both the first and second year, and 129 had knee MRs for both years. On comparing serial MRs, regression was observed in one hip and one knee, and complete resolution in four knees ( Table 4) . The four patients with complete resolution of lesions ranged in age from 2 years 8 months to 14 years 8 months at primary diagnosis, and 3 years 2 months to 6 years 6 months at time of alloHCT. Three of the four were skeletally immature as evidenced by physeal patency at time of alloHCT and were shown to have epiphyseal involvement of o30%. The patient with closed physes had epiphyseal involvement of at least 30%. Three of the four patients had a primary diagnosis of ALL and one had AML. All four patients were of healthy body weight; all had received TBI. Two received 6/6 HLA-matched sibling and two 6/6 HLA-matched unrelated donor cells. Three patients developed acute grade 1 GVHD; one developed no acute GVHD. All four developed chronic GVHD (two limited, two extensive and all four with a duration of o6 months).
New cases of osteonecrosis were identified in one hip and five knees, as given in (Table 4) . Among the 13 involved hips identified during follow-up, 4 have undergone total hip arthroplasty. Two of these had total hip arthroplasty before alloHCT and two afterward. In one patient, transient improvement in symptoms was documented after alloHCT, but subsequent progression required total hip arthroplasty. All of these patients underwent core decompressions of the involved joints before total hip arthroplasty.
Risk factors
Among the various risk factors studied, only pre-alloHCT osteonecrosis status (odds ratio (OR) 13.50; 95% CI 2.64 --68.92) and age X10 years at the time of alloHCT (OR 4.00; 95% CI 1.00 --16.67) were associated with greater odds of osteonecrosis in the 3 All patients (N = 149) Figure 2 . CI of osteonecrosis. Note: The y-intercept has been shown to be 12% (s.e. 2.68%), to emphasize that 14 patients were already known to have osteonecrosis at the time of alloHCT because of MR done before alloHCT.
years following alloHCT (Table 5 ). Black race was found to be significant on univariate analysis P ¼ 0.0431, but was not significant in models when patients with sickle cell disease were excluded. Other risk factors studied were not associated with an increased risk of osteonecrosis.
DISCUSSION
Our analysis of prospectively acquired longitudinal MRs of hips and knees revealed a prevalence of osteonecrosis in almost 30% of the children in the first 3 years after a single alloHCT. Although knees were more often involved, hip involvement was more extensive. We observed complete resolution of osteonecrosis after alloHCT in two patients' hips and six patients' knees. Of those, one had osteonecrosis lesion involving 430% of the epiphyseal surface before alloHCT. The prevalence of 30% is higher than previously reported rates that have been based on symptoms or less sensitive diagnostic techniques, but approach rates reported in MR-based studies; 12 --16,26 --30 symptom-based studies may under report earlystage osteonecrosis. As we focused only on epiphyseal lesions of hips and knees, 3 our findings may underestimate osteonecrosisassociated skeletal morbidity.
Aplastic anemia and ALL are well recognized risk factors for osteonecrosis following HCT; 2,9 we found no association in our post-alloHCT cohort. Our results conflict with those of our previous study, 19 where we evaluated risk factors for osteonecrosis before alloHCT and found some indication that a primary diagnosis of aplastic anemia or lymphoid malignancies may be a risk factor. As none of the published studies considered pre-alloHCT status, this discrepancy may be attributable to our risk factor analysis model adjusted for pre-alloHCT status.
The median time to development of osteonecrosis in our MRbased study was 12.3 months, a much shorter time period than reported in previous studies. 3, 7, 8, 10, 12, 31 We found that only age 410 years and preexisting osteonecrosis were predictive of an osteonecrosis in the 3 years following alloHCT. When future interventions that target early detection and prevention of Cases that showed regression of the osteonecrotic lesion. osteonecrosis in the first 3 years following transplant are available, older children and children with existing lesions will be prime candidates for screening.
Older age has been consistently recognized as a risk factor for osteonecrosis. 4, 8 White race has also been implicated as a risk factor for osteonecrosis. 32 We found no such association in our study population. Race was found to be statistically significant on univariate analysis but as sickle cell disease is strongly associated with black race, 25 we repeated the analysis after excluding sickle cell patients and found no such association. Our cohort included 16 sickle cell patients, of whom 8 were found to have osteonecrosis. Osteonecrosis is a well-known morbidity of sickle cell disease that has been positively associated with the frequency of vaso-occlusive pain crises and elevated hematocrit. 33 This morbidity has been reported in 10 --16% of symptomatic patients assessed radiographically 30, 34, 35 and in up to 40% of patients radiographically examined regardless of symptoms. 29 The high 50% prevalence of osteonecrosis we found in our sickle cell patients is similar to the MRdetected incidence of 65% reported after a follow-up period of 4 --5 years. 36 Unlike other investigators, 10, 13 we found no significant increase in risk for osteonecrosis among those who received TBI, possibly because our patients received very small doses of radiation per fraction (150 cGy per fraction twice daily).
The findings that pre-alloHCT osteonecrosis status was a risk factor for post-alloHCT osteonecrosis, and that GVHD was not an important risk factor during 3 years of follow-up, supports the multiple hit theory of osteonecrosis; 37, 38 steroid exposure imparts secondary rather than primary insult on the osteonecrosis pathway. Previous investigations, primarily conducted in adult populations, have identified an association between a higher grade or longer duration of GVHD (acute or chronic) and osteonecrosis, 2, 3, 7, 8, 11, 39, 40 attributing risk to prolonged exposure to steroids. We, however, found no such association. Prolonged exposure to steroids was not a prominent characteristic of our population. In our study, only 12% of children developed GVHD that required steroid therapy treatment for 46 months. As our For race analysis, sickle cell patients were excluded.
Osteonecrosis in children after alloHCT S Sharma et al population was followed for only 3 years post-alloHCT, it is possible that children in our cohort with chronic GVHD who eventually experience prolonged steroid exposure will develop osteonecrosis. Our analysis underscores the importance of prealloHCT therapeutic exposures, and the likelihood of osteonecrosis following alloHCT, and encourages us to explore novel options to curtail the compounding osteotoxic effect of glucocorticoids. 41 Another compelling finding in our study was regression or resolution of post-alloHCT osteonecrosis in several children. Of the patients whose osteonecrosis resolved completely, one initially had 430% epiphyseal involvement. As a standard of care at our institution, all children with osteonecrosis are managed conservatively until pain or restricted movement develops. At that time, analgesics and/or surgical options are offered. Whether these osteonecrosis regressions were the natural course of disease, a response to joint protection measures instituted in physical therapy 42 or a result of a protective effect of alloHCT is unknown. Our data preclude us from making definitive conclusions about osteonecrosis recovery because of alloHCT. However, limited evidence 43 --46 suggests that stem cells have a role in regenerative medicine. This reparative phenomenon may in part be attributed to MSCs or primitive hematopoietic cells with osteoblastic potential 43 engrafted during alloHCT. Increased chemotaxis by cytokines released from the necrosed bone may also facilitate MSC homing and vascular proliferation. 47, 48 Our findings should be interpreted with caution, as the diverse primary diagnoses limited our ability to estimate the effect of disease pathophysiology or its treatment on the evolution of osteonecrosis. Because our study population was slightly older than patients who did not receive imaging, and older age has been consistently associated with development of osteonecrosis, our estimated incidence for osteonecrosis in the first 3 years following alloHCT may be inflated. Finally, although the lesions we detected in this cohort developed during the first 3 years after alloHCT, our study results do not provide information needed to ascertain delayed onset osteonecrosis in this population. Despite these limitations, we provide information about the prevalence and risk factors for development of osteonecrosis during the first 3 years after alloHCT among children.
Our results led us to conclude that future screening and preventive strategies for osteonecrosis in children undergoing alloHCT should focus on pre-alloHCT risk factors among children who are 410 years of age. We recommend prospective controlled trials to determine the roles of physical therapy, MSC therapy and other novel interventions for treating early osteonecrotic lesions.
